MedTrace Logo

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

NCT04032847 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).

Conditions

  • Advanced Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

ATL001

ATL001 infusion

DRUG

Pembrolizumab

Checkpoint inhibitor

Sponsors & Collaborators

  • Achilles Therapeutics UK Limited

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Achilles Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2024-09-26
Completion
2024-09-26
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04032847 on ClinicalTrials.gov